Anti-Human HLA-DP (MHC Class II) Monomorphic – Purified

This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This purified antibody is stable when stored at 2-8°C. Do not freeze.

Next Day Ambient

Clone B7/21 recognizes a monomorphic epitope on human HLA-DP1, -DP2, -DP3, -DP4, and -DP5. It does not cross-react with HLA-DR or HLA-DQ.

HLA-DP antibody, clone B7/21, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DP isotype (HLA-DP). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation¹. HLA-DP consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain² encoded by the HLA-DPA1 and HLA-DPB1 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens³. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling⁴. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation⁵ and can transduce signals into T cells, enhancing T cell proliferation and activity⁶. High HLA-DP expression is associated with an increased risk of graft-versus-host disease⁷. Specific alleles of HLA-DP are associated with autoimmune diseases, including rheumatoid arthritis⁸.

HLA-DP is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.

1. Holling TM, et al. (2004) Hum Immunol. 65(4):282-90.
2. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25.
3. Wieczorek M, et al. (2017) Front Immunol. 8:292.
4. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921.
5. Barnaba V, et al. (1994) Eur J Immunol. 24(1):71-5.
6. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60.
7. Petersdorf EW, et al. (2015) N Engl J Med. 373(7):599-609.
8. Raychaudhuri S, et al. (2012) Nat Genet. 44(3):291-6.